Pfizer has agreed to acquire Metsera for up to $7.3 billion, marking a strategic return to the obesity and metabolic drug market following internal clinical setbacks earlier in 2025. The deal includes a $4.9 billion upfront payment plus contingent value rights tied to key clinical and regulatory milestones on Metsera’s pipeline, which features injectable and oral GLP-1 receptor agonists and amylin analogs aimed at improving dosing convenience and tolerability. This acquisition expands Pfizer’s obesity portfolio alongside ongoing metabolic programs, positioning the pharma giant as a formidable competitor in a rapidly evolving sector. Industry analysts highlight the potential blockbuster sales and competitive advantages the combined pipeline offers based on positive phase II trial results and anticipated phase III readouts in 2026.